ADARx Pharmaceuticals debuts on Nasdaq with $446M IPO

ADARx Pharmaceuticals went public on Nasdaq with an IPO valued at $446.3 million. AbbVie invested an additional $89 million in the company. ADARx develops drugs based on RNAi technology, with onvuzosiran as its most advanced project.